Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
Type:
Application
Filed:
January 30, 2018
Publication date:
January 10, 2019
Applicant:
Bayer Intellectual Property GmbH
Inventors:
Joachim LUITHLE, Frank-Gerhard BÖß, Christina ERB, Katrin SCHNIZLER, Timo FLESSNER, Marja van KAMPEN, Christoph METHFESSEL
Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Type:
Application
Filed:
March 5, 2018
Publication date:
September 13, 2018
Applicant:
Bayer Intellectual Property GmbH
Inventors:
Antje KAHNERT, David LIGHT, Doug SCHNEIDER, Renate PARRY, Noboru SATOZAWA, Tara HEITNER, Stefan STEIDL, Ulrike SCHUBERT
Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
Inventors:
Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, Julie Marley, Iain Pritchard
Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
Type:
Application
Filed:
March 16, 2018
Publication date:
July 19, 2018
Applicant:
Bayer Intellectual Property GmbH
Inventors:
Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.
Type:
Application
Filed:
November 3, 2017
Publication date:
June 7, 2018
Applicant:
Bayer Intellectual Property GmbH
Inventors:
Venkata-Rangarao KANIKANTI, Petra LANGE, Hans-Juergen HAMANN, Peter KLEINEBUDDE
Abstract: The present invention relates to a process for preparing substituted anthranilic acid derivatives of the formula (I) in which R1, R2, R3 and R4 are each as defined in the description, by conversion of compounds of the general formula (IV) in the presence of a palladium catalyst and carbon monoxide. The present invention likewise relates to compounds of the general formula (IV).
Type:
Grant
Filed:
April 20, 2017
Date of Patent:
May 15, 2018
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Thomas Himmler, Sergii Pazenok, Frank Volz, Norbert Lui
Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
Type:
Grant
Filed:
April 14, 2017
Date of Patent:
May 8, 2018
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
Abstract: The present invention relates to alternan-carboxylic acid esters, to processes for the preparation of alternan-carboxylic acid esters, and to compositions comprising alternan-carboxylic acid esters and to the use of alternan-carboxylic acid esters. The invention relates to alternan-carboxylic acid esters which are emulsifiers.
Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
Type:
Grant
Filed:
November 25, 2014
Date of Patent:
February 27, 2018
Assignee:
Bayer Intellectual Property GmbH
Inventors:
William Scott, Ningshu Liu, Manfred Möwes, Andrea Hägebarth, Ursula Mönning, Ulf Bömer
Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
Type:
Application
Filed:
July 21, 2017
Publication date:
November 16, 2017
Applicant:
Bayer Intellectual Property GmbH
Inventors:
Antje KAHNERT, Kerstin UNTERSCHEMMANN, Iring HEISLER, Charlotte KOPITZ, Joachim SCHUMACHER
Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.
Type:
Grant
Filed:
April 28, 2016
Date of Patent:
October 3, 2017
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
Abstract: The invention relates to a method for improving the utilization of the production potential of a genetically modified plant where the plant is treated with an effective amount of at least one compound of the formula (I) in which R1 to R3, X, L, n and Y have the meanings given in the description.
Type:
Grant
Filed:
December 16, 2009
Date of Patent:
September 19, 2017
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Peter Jeschke, Wolfram Andersch, Heike Hungenberg
Inventors:
Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
Abstract: Bis(difluoromethyl)pyrazole derivatives of the formula (I) in which the symbols R1, X and G are each as defined in the description, and agrochemically active salts, metal complexes and N-oxides thereof, and use thereof for controlling phytopathogenic harmful fungi, and also processes for preparing compounds of the formula (I).
Type:
Grant
Filed:
January 28, 2016
Date of Patent:
September 5, 2017
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Pierre Cristau, Sebastian Hoffmann, Joachim Kluth, Tomoki Tsuchiya, Pierre Wasnaire, Jurgen Benting, Daniela Portz, Ulrike Wachendorff-Neumann, Stefan Hillebrand
Abstract: Various methods for optimizing coating of medical devices, such as balloon catheters are disclosed. One method configures catheter balloon folds based on balloon diameter and volume. Other methods include using a specifically-sized protective sheath, using a vacuum, using pressure, pulling the balloon through a coating solution, using at least one spacer or a wick between at least one fold for metering a therapeutic coating into the folds of the balloon, placing an intermediate layer between the balloon and the therapeutic coating, placing a soluble film having a therapeutic agent around the catheter balloon or inside the folds, and any combination thereof. Balloon catheters and catheter balloons having a specific folding configuration, a specifically-sized protective sheath, an intermediate layer, or a soluble film are also disclosed.
Type:
Grant
Filed:
July 24, 2015
Date of Patent:
August 8, 2017
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Benjamin T. Ewing, Gregory G. Brucker, Scott A. Bednar, John R. Periard, Ashok A. Sharma, Steven D. Savage, Arthur E. Uber, Brian P. Dickerson
Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
Type:
Application
Filed:
April 14, 2017
Publication date:
August 3, 2017
Applicant:
Bayer Intellectual Property GmbH
Inventors:
Ulrich LÜCKING, Rolf BOHLMANN, Arne SCHOLZ, Gerhard SIEMEISTER, Mark Jean GNOTH, Ulf BÖMER, Dirk KOSEMUND, Philip LIENAU, Gerd RÜHTER, Carsten SCHULTZ-FADEMRECHT
Abstract: The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.
Type:
Grant
Filed:
June 9, 2014
Date of Patent:
July 25, 2017
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Timo Fleβner, Frank-Gerhard Böβ, Christina Erb, Frank-Thorsten Hafner, Katrin Schnizler, Dieter Lang, Joachim Luithle, Marja Van Kampen, Franz-Josef Van Der Staay
Abstract: A seeding machine (1) and method of use, for introducing seed material into a soil (11), with a first ploughing device for drawing at least one furrow into the soil and a filling device for closing the first furrow. A dust separator (5) separates air during the seeding process into an air component (13) and a dust component (7). A line from the dust separator delivers the dust component separated from the air component into the soil.
Type:
Grant
Filed:
March 12, 2013
Date of Patent:
July 11, 2017
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Adrian Christopher Arnold, Lubos Vrbka, Charles Andrew Chapple
Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.
Type:
Application
Filed:
January 4, 2017
Publication date:
June 29, 2017
Applicant:
Bayer Intellectual Property GmbH
Inventors:
Kanikanti VENKATA-RANGARAO, Petra LANGE, Hans-Jürgen HAMANN, Peter KLEINEBUDDE
Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
Type:
Grant
Filed:
January 5, 2017
Date of Patent:
May 22, 2018
Assignee:
Bayer Intellectual Property GMBH
Inventors:
Martin Hentemann, Jill Wood, William Scott, Martin Michels, Ann-Marie Campbell, Ann-Marie Bullion, Bruce R. Rowley, Aniko Redman